Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pigmentation disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Pigmentation disorders. Displaying page 1 of 1.
    EudraCT Number: 2011-000169-10 Sponsor Protocol Number: CUV101 Start Date*: 2011-04-08
    Sponsor Name:CLINUVEL PHARMACUETICALS LTD.
    Full Title: A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegm...
    Medical condition: Subjects affected by non-segmental vitiligo
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10062080 Pigmentation disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004536-29 Sponsor Protocol Number: CHUBX2017/44 Start Date*: 2022-12-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Efficacy and tolerance of the association of MTX and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (METVI)
    Medical condition: Progressive vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004110-10 Sponsor Protocol Number: 2ABC Start Date*: 2017-12-21
    Sponsor Name:Medical University of Warsaw
    Full Title: Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The t...
    Medical condition: Scar or cutis laxa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10039581 Scar conditions and fibrosis of skin LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10011692 Cutis laxa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000034-36 Sponsor Protocol Number: CHDR1734_CLS003-CO-PR-004 Start Date*: 2018-08-10
    Sponsor Name:Cutanea Life Sciences
    Full Title: A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin...
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001633-41 Sponsor Protocol Number: SONIA2 Start Date*: 2013-09-17
    Sponsor Name:University of Liverpool (UniLiv)
    Full Title: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria ...
    Medical condition: Alkaptonuria (AKU) - a serious, autosomal recessive, multisystem disorder.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10010331 - Congenital, familial and genetic disorders 10001689 Alkaptonuria PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000490-20 Sponsor Protocol Number: Galderma-Metvix Start Date*: 2018-02-08
    Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli"
    Full Title: Evaluation of efficacy, safety and patient¿s satisfaction of daylight photodynamic therapy (DL-PDT) in the treatment of actinic keratosis on the face and scalp and related field cancerization carri...
    Medical condition: actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    21.0 10040785 - Skin and subcutaneous tissue disorders 10064266 Skin hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002202-18 Sponsor Protocol Number: INT 07/07 Start Date*: 2008-01-11
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: CALENDULA POMADE VERSUS PLACEBO CREAM/CORTISONE CREAM (FLUORCORTOLONE) IN THE PREVENTION OF CUTANEOUS ERYTHEMA DUE TO BREAST IRRADIATION. A RANDOMIZED STUDY ON 60 PATIENTS
    Medical condition: Patients treated for the first time with radiotherapy to the residual breast after quadrantectomy for proven non-metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014982 HLGT
    9.1 10052164 LLT
    9.1 10038604 SOC
    9.1 10006289 HLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002678-19 Sponsor Protocol Number: SP148MP201 Start Date*: 2018-03-20
    Sponsor Name:SmartPractice
    Full Title: Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study
    Medical condition: Metal induced contact dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002418-11 Sponsor Protocol Number: RH01913 Start Date*: 2013-08-12
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A study to evaluate the effect of a 67% Sodium Bicarbonate containing toothpaste on Chlorhexidine Digluconate tooth staining
    Medical condition: Tooth discolouration (a labelled undesirable effect of Corsodyl 0.2% mouthwash)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10044032 Tooth discolouration PT
    14.1 10021881 - Infections and infestations 10018292 Gingivitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-004538-32 Sponsor Protocol Number: LIMTOP-I Start Date*: 2012-04-04
    Sponsor Name:Moberg Derma
    Full Title: A double-blind, randomized, multi-centre, vehicle-controlled study of efficacy and safety of a new topical formulation with imiquimod (Limtop) applied 1,3 or 7 times weekly during 2 x 2 weeks treat...
    Medical condition: 5-20 clinically confirmed, palpable or visible (grade I or II according to modified Olsen score), nonhyperkeratotic, nonhypertrophic, AK lesions located within a contiguous (25 - 100 cm²) area on t...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002583-80 Sponsor Protocol Number: 38814 Start Date*: 2013-09-06
    Sponsor Name:Department of Dermatology, Bispebjerg University Hospital
    Full Title: Treatment of Actinic Keratoses with Ingenol Mebutate and topical glucocorticosteroid - a safety study
    Medical condition: Actinic Keratoses
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000956-42 Sponsor Protocol Number: VRX-RET-E22-304 Start Date*: 2006-09-20
    Sponsor Name:Valeant Pharmaceuticals, North America
    Full Title: A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)
    Medical condition: Adult epilepsy patients with partial-onset seizures
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) BE (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022777-34 Sponsor Protocol Number: RTG113413 Start Date*: 2011-02-01
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905).
    Medical condition: Epilepsy - partial-onset seizures with or without secondary generalisation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10065336 Partial epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IT (Completed) ES (Prematurely Ended) BG (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000588-99 Sponsor Protocol Number: BLU-285-2203 Start Date*: 2019-03-15
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indole...
    Medical condition: Indolent Systemic Mastocytosis (ISM)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042949 Systemic mastocytosis PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056452 Indolent systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005006-35 Sponsor Protocol Number: RM-493-022 Start Date*: 2018-05-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto...
    Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) GR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:11:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA